Feedback / Questions
POZ-apomorphine (SER-252) - Serina Therap
https://www.globenewswire.com/news-release/2025/12/10/3203527/0/en/Serina-Therapeutics-Submits-Complete-Response-to-FDA-Clinical-Hold-Letter-for-SER-252-Program.html
Dec 10, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next